---
title: "TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer | RNAZ Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288572885.md"
description: "TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer | RNAZ Stock News"
datetime: "2026-06-03T04:05:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288572885.md)
  - [en](https://longbridge.com/en/news/288572885.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288572885.md)
---

# TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer | RNAZ Stock News

TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer | RNAZ Stock News

### Related Stocks

- [RNAZ.US](https://longbridge.com/en/quote/RNAZ.US.md)

## Related News & Research

- [TransCode Therapeutics to Host R&D Webcast on June 18, 2026 | RNAZ Stock News](https://longbridge.com/en/news/289052490.md)
- [EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study](https://longbridge.com/en/news/288573090.md)
- [Why Anthropic's 'safe' Mythos-class model won't answer questions about cancer](https://longbridge.com/en/news/289277338.md)
- [08:01 ETNew York Proton Center Presents Advances in Proton Therapy Across Multiple Cancers at PTCOG 64](https://longbridge.com/en/news/289461179.md)
- [This AI Tool Could Spot Cancer Years Before Diagnosis— And The FDA Is Taking A Look](https://longbridge.com/en/news/289192227.md)